daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

NCT07588945 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

438

Enrollment

OTHER

Sponsor class

Conditions

Transplant-Related Disorder

Interventions

DRUG: Ruxolitinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China